Jean-Paul Prieels holds a PhD in Biochemistry from Université Libre de Bruxelles (ULB) in Belgium.
After 10 years in the academic world (ULB, ICP-UCL, Duke University), he started his industrial career at Petrofina in 1983 as Biotechnology Manager and joined GlaxoSmithKline Biologicals in 1987.
His responsibilities gradually expanded from leading the extramural R&D team to becoming responsible for preclinical vaccine R&D activities in Rixensart, Belgium.
He retired as Senior Vice President of WW Research & Development in 2011. He was instrumental in the development of several commercially available vaccines, such as Rotarix, Cervarix, Synflorix, and Shingrix.
Today, he is CEO of Conveyxo and member of the supervisory board at 20Med Therapeutics (NL), PDC*line Pharma and Quantoom Biosciences (B), Leukocare (Ge) and Nouscom (CH).